Delayed Haematological Toxicity in Patients Treated with 177Lu-octreotate Peptide Receptor Radiotherapy (PRRT) for Metastatic Neuroendocrine Tumors (NETs)
Introduction: PRRT is associated with a high tumor control rate and early toxicity seems acceptable (haematological grade 3-4 toxicity: 11.3%). Long-term monitoring of haematological toxicity is unavailable.
Aim(s): To evaluate delayed haematological toxicity after PRRT for metastatic NETs.
Materials and methods: Twenty pts treated with 177-Lu PRRT between 2005 and 2013 for a progressive metastatic digestive NET (four courses every eight weeks, 7.9 GBq/injection) had prolonged follow-up with blood cell tests.
Conference: 11th Annual ENETSConcerence (2014)
To read the full abstract, please log into your ENETS Member account.